WH Bakker

Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide.

E. P. Krenning, WH Bakker, P P Kooij et al. · PubMed · 1992 · 422 citations

Engineering, Pathology, Positron Emission Tomography +18

Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy.

M. de Jong, W A Breeman, WH Bakker et al. · PubMed · 1998 · 210 citations

Engineering, Chemoprevention Strategy, In-labeled Somatostatin +21

Scintigraphy and radionuclide therapy with [indium-111-labelled-diethyl triamine penta-acetic acid-D-Phe1]-octreotide.

E. P. Krenning, Roelf Valkema, P.P.M. Kooij et al. · PubMed · 1999 · 118 citations

Engineering, Positron Emission Tomography, Theranostics +16

Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.

D J Kwekkeboom, P.P.M. Kooij, WH Bakker et al. · PubMed · 1999 · 107 citations

Phase I study of therapy with Y-90-SMT487 (octreother) in patients with somatostatin receptor (SS-R) positive tumors.

Roelf Valkema, François Jamar, Stanislas Pauwels et al. · DIAL (Catholic University of Leuven) · 2002 · 18 citations

Positive Tumors, Endocrine Oncology, Oncology +8